% | $
Quotes you view appear here for quick access.

công ty Questcor Pharmaceuticals Message Board

good72day 8 posts  |  Last Activity: Oct 6, 2015 2:14 PM Member since: May 14, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Cramer's trashing actually helped MNK

    by crabdippers Oct 6, 2015 8:06 AM
    good72day good72day Oct 6, 2015 2:14 PM Flag

    Hi, Nomad, Some of the oldies thought you went to the short side.
    Good to see you back, though!

  • Reply to

    MNK lawyers resigned???

    by rockowayman Oct 6, 2015 10:31 AM
    good72day good72day Oct 6, 2015 2:12 PM Flag

    Here is a message from Cole:
    I believe he was referring to Peter Edwards, who left the company in the spring to become the GC at the BAX spinco Baxalta…Terry has been with MNK as GC ever since…

  • Reply to

    Any corporate buyers?

    by naglecolin Sep 28, 2015 8:20 PM
    good72day good72day Oct 5, 2015 2:58 PM Flag

    Start with S. *&^

  • Reply to

    What ever happened to ALS study?

    by caffeinsomniac Sep 29, 2015 3:41 PM
    good72day good72day Sep 29, 2015 6:51 PM Flag

    They said they still were still reviewing the data and they plan to have a more clear picture of what is next step by the end of this year.

  • Reply to

    Lupus data still expected in Sept?

    by bullrunbullrun Sep 28, 2015 10:17 AM
    good72day good72day Sep 28, 2015 11:20 PM Flag

    I asked them through email and they said they didn't want to release the data before the annual meeting.( This is some kind of meeting policy)

  • Reply to

    Lupus data still expected in Sept?

    by bullrunbullrun Sep 28, 2015 10:17 AM
    good72day good72day Sep 28, 2015 10:47 AM Flag

    2015 ACR/ARHP Annual Meeting in San Francisco, CA on November 6 – 11

  • good72day good72day Aug 2, 2015 11:04 PM Flag

    Sorry, Noquick, It is just copy and paste.

  • BACKGROUND: Infantile spasms (IS) typically occur within the
    first year of life. Children with IS frequently experience spasms,
    hypsarrhythmia and psychomotor retardation. H.P. Acthar Gel® is an
    adrenocorticotropic hormone (ACTH) analogue that is FDA approved
    for the treatment of IS. Evidence-based guidelines recommend the use
    of ACTH as first-line therapy for IS. Long-term prognosis of IS patients,
    specifically neurodevelopmental outcomes, is relatively poor. Initiating
    ACTH therapy soon after diagnosis may improve favorable outcomes
    and may decrease the risk of mental retardation. Prompt diagnosis and
    treatment may prevent developmental delays and may also reduce
    healthcare utilization and costs.
    OBJECTIVE: We compared the economic consequences of initiating
    ACTH early (within 30 days of IS diagnosis) with that of late ACTH
    treatment ( 30 days after diagnosis).
    METHODS: All patients 30
    days of the index date). Patients with continuous health plan enrollment
    for 3-months prior and 12-months post index date were included in
    this retrospective analysis. We estimated and compared the healthcare
    resource use and costs (inpatient, outpatient, and pharmacy) separately
    for patients in the two groups. Multivariate regression models were
    constructed to adjust for gender and prior hospitalizations.
    RESULTS: We identified a total of 259 IS patients who met our study
    eligibility criteria. 197 (76%) patients used ACTH early and 62 (24%)
    patients were late users of ACTH. Over the one-year follow-up from IS
    diagnosis, early users had 16% fewer outpatient visits (95% CI: -13% to
    -19%) and 15% less overall healthcare resource utilization (95% CI: -13%
    to -18%) when compared to late ACTH users. Unadjusted 12-month
    total outpatient costs (excluding the costs of administering ACTH)
    for early users were 30% lower ($23,200 for early users as compared
    to $33,500 for late users; 95% CI: -10% to -50%) as were the total
    medication costs excluding cost of ACTH (50% reduction; 95% CI: -20%
    to -70%). After adjusting for gender and prior hospitalizations, the
    relative rate ratio of outpatient visits (0.89; 95% CI: 0.85 to 0.92), overall
    healthcare resource utilization (0.91; 95% CI: 0.88 to 0.94) and total
    medication costs (excluding ACTH costs) (0.5; 95% CI: 0.3 to 0.8) were
    statistically significantly lower in early ACTH users than late users.
    CONCLUSION: In this analysis, we found that the economic
    consequences of treating patients with ACTH within 30 days of IS
    diagnosis may be associated with decreases in overall healthcare
    resource use, outpatient visits and total medication costs.

93.600.00(0.00%)Aug 14 4:00 PMEDT